Coultreon Biopharma, formerly a Galapagos-linked asset platform focused on an oral immunology strategy, raised a $125 million Series A to advance its lead pill designed to selectively inhibit SIK3. The company’s financing supports Phase 2 trials in psoriasis and ulcerative colitis. Coultreon’s strategy is framed around “pills that emulate” the potency and durability often sought from injectable biologics, aiming to target an immunology mechanism distinct from conventional pathway blocks. The funding adds to a growing pipeline-in-a-pill approach for autoimmune indications, where oral dosing is increasingly pursued to improve adherence and simplify long-term management.